WO2011092367A1 - Procedimiento para la producción de interferón alfa 5 - Google Patents
Procedimiento para la producción de interferón alfa 5 Download PDFInfo
- Publication number
- WO2011092367A1 WO2011092367A1 PCT/ES2011/070057 ES2011070057W WO2011092367A1 WO 2011092367 A1 WO2011092367 A1 WO 2011092367A1 ES 2011070057 W ES2011070057 W ES 2011070057W WO 2011092367 A1 WO2011092367 A1 WO 2011092367A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ifna5
- protein
- coli
- hifna5
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
Definitions
- the present invention relates to a process for producing an interferon alpha 5 protein (IFNa5) by expression in an IFNa5-producing Escherichia coli host cell, where the incorporation of an extra methionine residue at the N-terminal end is minimized. of the polypeptide chain as well as the generation of its oxidized species.
- the IFNa5 protein can be purified by an effective method to produce biologically active IFNa5.
- Interferons are a group of naturally occurring pleiotropic glycoproteins known as cytokines, secreted from different cell types (epithelial cells, fibroblasts, lymphocytes, macrophages) by induction of a series of stimulations (viruses, bacteria, cells, tumors and macromolecules) and are endowed with antiviral, antiproliferative and immunomodulatory properties as well as analgesic action. After endogenous production or administration, interferon interacts with specific receptors on the cell surface and begins signal transduction through the cytoplasm to the nucleus, which induces the expression of genes encoding specific proteins that have antiviral activity. and immunostimulatory.
- interferons The medical potential of interferons has been recognized, as demonstrated by the approval of different types of interferons for use in humans, such as IFNla (Rebif, Avonex), IFNlb (Betaseron), as drugs for the treatment of multiple sclerosis, and recombinant human IFNa2a (Roferon A) and IFNa2b (Intron A), as drugs for the treatment of cancers and viral diseases.
- type I IFNs [all type IFNs I bind to a specific cell surface receptor complex known as the IFN-alpha receptor (IFNAR) - type I IFNs in humans are IFN alpha (IFN- ⁇ ), IFN beta (IFN- ⁇ ) and IFN omega (I FN- ⁇ )], (ii) type II IFN [type II IFN binds to an IFN-gamma receptor (IFNGR) - type II IFN in humans is IFN gamma (IFN- ⁇ )], and type III IFN [type III IFNs signal through a receptor complex consisting of IL10R2 and IFNLR1].
- the alpha and beta IFNs known as type I IFNs, are structurally related, are stable at acidic pH and compete for the same cell receptor (IFNAR).
- alpha, beta and gamma IFNs can be produced recombinantly with the double advantage of achieving much larger quantities of product compared to those obtained by isolating natural sources (leukocytes, fibroblasts, lymphocytes) and reducing the complexity of Purification procedures and product safety control.
- most of the commercially available pharmaceutical grade recombinant IFN is produced and purified from Escherichia coli.
- E. coli recombinant protein expression system has been, and still is, the system of choice for IFN production.
- IFN genes have no introns and protein products in general are not glycosylated.
- E. coli can grow rapidly at high cell densities and the strains used for the production of recombinant proteins have been genetically modified so that they are generally considered safe for large-scale fermentation.
- IFN cDNA expression was achieved directly in E. coli shortly after it was first cloned [Goedell et al. Nature., 287, 411-416, 1980; Pestka, S. Arch. Biochem. Biophys., 221 (1), 1-37, 1983; Mizoguchi et al. DNA , 4, 221-32, 1985; Pestka et al. Ann. Rev. Biochem., 56, 727-777, 1987; Baron and Narula. Critical revie s in Biotechnology, 10 (3), 179-190, 1990].
- IFN alpha IFN alpha
- IFNa has been one of the first proteins produced by E. coli with recombinant DNA technology [Derynck et al., Nature, 287, 193-197, 1980; Nagata et al., Nature, 284, 316-320, 1980].
- IFNs expressed in E. coli shows some problems. IFNs expressed in large quantities in E. coli frequently precipitate into insoluble aggregates called inclusion bodies (IC) [S aminathan et al., Prot Express. Purif. , 15, 236-242, 1999; Bedarrain et al., Biotechnol. Appl. Biochem , 33, 173-182, 2001; Srivasta et al. Prot. Express. Purif 41, 313-322, 2005] which are, in general, misfolded proteins and thus biologically inactive [Villaverde and Carrio, Biotechnol. Lett. , 25, 1385-1395, 2003].
- IC inclusion bodies
- the inventors have now surprisingly found that the concentration of trace elements (trace elements) in the fermentation medium plays an important role in the post-translational modifications of IFNa5.
- concentration of trace elements in the fermentation medium plays an important role in the post-translational modifications of IFNa5.
- Example 4 shows that the formation of the oxidized methionlated form of human IFN alpha-5 (hIFNa5) is eliminated and the amount of the acetylated forms of hIFNa5 is reduced twice (i.e., in half), when 1 liter (L) of carbon feed solution contains from about 3.0 mL to about 3.7 mL of a stock solution of trace elements and, preferably, the average specific crop growth rate ( ⁇ ) after induction is equal or greater than 0.17.
- the invention relates to a process for producing an interferon alpha 5 protein (IFNa5) by expression in an IFNa5 producing Escher ⁇ ch ⁇ a coli host cell, comprising:
- said fermentation medium is free of components of animal origin or from yeast, and
- said carbon feed solution comprises a carbon source and from about 3.0 to about 3.7 mL of a trace element solution per liter of added carbon feed solution;
- said E. coli host cell is a protease deficient E. coli strain, such as the E. coli Ion ⁇ / ompT ⁇ protease deficient host strain, preferably an E. coli strain BL21, most preferably a strain of E. coli BL21 (DE3).
- a protease deficient E. coli strain such as the E. coli Ion ⁇ / ompT ⁇ protease deficient host strain, preferably an E. coli strain BL21, most preferably a strain of E. coli BL21 (DE3).
- the conditions of step b) comprise induction with IPTG.
- step c) of isolating and purifying the expressed IFNa5 protein successively comprises, after lysis of E. coli host cells, isolating said IFNa5 protein in the form of inclusion bodies (CI) by subjecting said CI a so lubi 1 iz ation, and the resulting mixture to an oxidative renaturation and a progressive series of chromatographies comprising:
- step 1) subjecting a mixture comprising renatured IFNa5 to hydrophobic interaction chromatography; 2) subject the solution obtained in step 1) to an anion exchange chromatography;
- step 3 subject the solution obtained in step 2) to a first cation exchange chromatography
- step 4) subjecting the solution obtained in step 3) to a second cation exchange chromatography, wherein said solution, optionally, is diluted with a buffer comprising methionine,
- said IFNa5 is preferably a human IFNa5 (hIFNa5).
- Figure 1 shows the flow chart of the construction of an IFNa5 producing strain.
- Figure 2 shows the results of the restriction analysis of the plasmid pET28-IFN alpha-5 primary plasmid.
- Lanes 1-3 and 5-7 restriction analysis of pET28-IFN alpha-5; lanes 1 and 5: pET28-IFN alpha-5 / BamHI; lanes 2 and 6: pET28-IFN alpha-5 / NdeI; lanes 3 and 7: pET28-IFN alpha-5 / NdeI + BamHI; lanes 4 and 8: pET28-IFN alpha-5 uncut.
- the size of the marker DNA bands (Gene Ruler DNA Ladder Mix, Fermentas, Lithuania) in pairs of kilobases (kpb) is indicated.
- Figure 3 shows the results of the restriction analysis of the IFN alpha 5 intermediate plasmid.
- the plasmid was derived from a single clone.
- the size of the marker DNA bands (Gene Ruler DNA Ladder Mix, Fermentas, Lithuania) is indicated in kbp. Expected fragment sizes (in bp) are given in parentheses.
- Lane 1 pUC57-IFN alpha-5 / PstI (28; 3197);
- lane 2 pUC57-IFN alpha-5 / PvuII (455; 406; 2364);
- lane 3 pUC57-IFN alpha-5 / NdeI (250; 2975).
- Figure 4 shows the complete nucleotide sequence of the human IFN alpha-5 coding fragment (hIFNa5) optimized for expression in E. coli by changing some codons with the less frequent codons used in E. coli. Nucleotide substitutions are underlined.
- Figure 5 shows the results of the restriction analysis of plasmid pET21-IFN alpha-5. The plasmid was derived from a single clone. The size of the marker DNA bands (Gene Ruler DNA Ladder Mix, Fermentas, Lithuania) is indicated in kbp. Expected fragment sizes (in bp) are given in parentheses.
- Lane 1 pET21-IFN alpha-5 / PagI (673; 817; 1008; 3423); lane 2: pET21-IFN alpha-5 / PstI (1352; 4569); lane 3: pET21-IFN alpha-5 / NdeI + BamHI (516; 5405).
- Figure 6 shows the expression of the recombinant IFNa5 protein.
- E. coli BL21 (DE3) pET21-IFN alpha-5 cell cultures taken from 9 colonies (lanes 1-9) were grown in 750 mL bottles (LB medium, 250 mL volume) at 37 ° C until D0 6 or about 1.2. Expression of the target protein was induced with 1 mM IPTG for 2.5 hours. Total cell protein samples were run alongside BioRad protein markers (in kDa indicated on the left) in a 15% SDS-PAGE followed by Coomassie blue staining.
- Figure 7 shows the flow chart of the biosynthesis of recombinant hIFNa5.
- Figure 8 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by SDS-PAGE (14%) both under reducing (Figure 8A) and non-reducing conditions (Figure 8B) of the hIFNa5 protein (the figure shows the results of three lots of large-scale purification of hIFNa5 protein).
- Figure 9 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by "reverse phase high resolution liquid chromatography” (RP-HPLC) analysis (the figure shows the results of three lots of large-scale protein purification hIFNa5).
- RP-HPLC reverse phase high resolution liquid chromatography
- Figure 10 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by "molecular exclusion HPLC" (SE-HPLC) analysis (the figure shows the results of three large-scale purification lots of hIFNa5 protein).
- Figure 11 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by isoelectric focusing analysis (the figure shows the results of three large-scale purification lots of hIFNa5 protein).
- Lanes 1, 11 pl standards (Amersham Pharmacia); lanes 2, 3, 4: recombinant hIFNa5, 15 g; lanes 5, 6, 7: recombinant hIFNa5, 5 g; lanes 8, 9, 10: recombinant hIFNa5, 1] ig.
- Figure 12 shows the large-scale three-batch peptide mapping chromatograms of purified and formulated recombinant hIFNa5 preparations according to the invention.
- interferon alfa 5" refers to a protein produced by leukocytes that is apparently primarily involved in the innate immune response against viral infection, capable of binding to a specific cell surface receptor complex known as the IFNa receptor (IFNAR).
- IFNa receptor IFNa receptor
- IFNa5 proteins are described, for example in WO 83/02459
- IFNa5 includes proteins that have (i) an amino acid sequence that is at least substantially identical to the amino acid sequence of a native IFNa5 protein and (ii) a biological activity that is common to a native IFNa5.
- substantially identical amino acid sequence means that the sequences are identical or different in one or more amino acid changes (i.e. deletions, additions, substitutions) that do not produce an adverse functional dissimilarity between the synthetic protein and the native IFNa5, for example, proteins IFNa5 that have at least 70% identity with a of the aforementioned IFNa5 proteins.
- X% identity between an IFNa5 protein (P) and a reference IFNa5 protein (R), means that when the two sequences are aligned, X% of P amino acids are identical to the corresponding amino acids in the R sequence or are exchanged for an amino acid of the same group, such as:
- amino acids with non-polar R groups alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine;
- - amino acids with uncharged polar R groups glycine, serine, threonine, cistern, tyrosine, asparagine and glutamine;
- amino acids with charged R polar groups (negatively charged at pH 6.0): aspartic acid and glutamic acid;
- amino acids that have phenyl groups phenylalanine, tryptophan, tyrosine.
- the term "IFNa5-producing E. coli host cell” refers to an E. coli host cell that has been genetically engineered to produce a protein that possesses biological activity associated with an IFNa5.
- the E. host cell. coli is a strain of E. coli protease deficient, such as the host strain of E. coli protease deficient Ion ⁇ / ompT ⁇ , preferably a strain of E. coli BL21, most preferably a strain of E. coli BL21 ( DE3).
- biological activity of an IFNa5 refers to any biological activity of said IFNa5 that includes the therapeutic activity of said IFNa5.
- WO 83/02459 discloses that IFNa5 shows antiviral activity against DNA and RNA viruses, cell growth activity and ability to regulate the production of intracellular enzymes and other substances produced by the cell; based on this, it is expected that IFNa5 can be used to treat viral infections (eg, chronic hepatitis B infection), tumors and cancer.
- the term "fermentation medium” is "free of components of animal origin or from yeast” as used herein means that there is no risk of transmitting agents that produce spongiform encephalopathy through medicinal products, there is no evidence of BSE contamination or cases of ECJv associated with pharmaceutical products.
- the product is free of vestigial amounts of contaminating proteins from yeast cells.
- the invention relates to a process for producing an interferon alfa 5 protein (IFNa5) by expression in an IFNa5-producing Escherichia coli host cell, hereinafter the "process of the invention", comprising:
- said IFNa5 that can be produced according to the process of the invention is an IFNa5 protein that is substantially identical to the native IFNa5, that is, a protein that is produced by an IFNa5-producing E. coli host cell. which has been transformed with a gene encoding IFNa5 or a modification thereof encoding a protein that has (1) an amino acid sequence that is at least substantially identical to the amino acid sequence of a native IFNa5 and (2) a biological activity which is common to a native IFNa5.
- said IFNa5 is hIFNa5.
- the recombinant IFNa5 produced according to the method of the invention is an IFNa5 having the amino acid sequence shown in SEQ ID NO: 1 ( Figure 4) corresponding to the mature hIFNa5 having an extra methionine residue. at the N-terminal end of the polypeptide chain.
- an IFNa5-producing E. coli host cell [step a)] is provided.
- the E. coli host cell is a protease deficient E. coli strain, such as the strain. E. coli host deficient in Ion ⁇ / ompT ⁇ proteases, preferably a strain of E. coli BL21, more preferably a strain of E. coli BL21 (DE3).
- the IFNa5-producing E. coli host cell can be obtained by conventional methods and protocols for cloning and expressing an IFNa5 [eg, Sambrook et al. Molecular cloning: A Laboratory Manual. Second ed. , CSH Laboratory, Cold Spring Harbor, 1989; Current Protocols in Molecular Biology, vol. 1-3 (Ausubel F.M. et al., Ed.) John Wiley & Sons, Inc., Brooklyn, New York, 1994-1998].
- the cloning and expression of a gene encoding an IFNa5 and the construction of the bacterial strain that produces the recombinant IFNa5 protein i.e., the IFNa5-producing E.
- coli host cell can be performed according to a method comprising the cloning of the cDNA of the gene encoding an IFNa5, the modification of the DNA sequence of said gene to optimize its expression in E. coli, the construction of an expression plasmid, the transformation of the selected plasmid into a strain adequate E. coli and the selection of expression / induction conditions.
- Example 1 describes the construction of an IFNa5 producing E. coli host cell.
- the E. coli host cell when the E. coli host cell is a protease deficient E. coli strain, such as E. coli strain BL21 (DE3), said host cell is transformed with a vector comprising a sequence encoding the IFNa5 protein under the control of an inducible promoter; in that case, the expression of the protein requires the addition of an inducer, such as, for example, isopropyl-D-thiogalactopyranoside (IPTG).
- an inducer such as, for example, isopropyl-D-thiogalactopyranoside (IPTG).
- IPTG isopropyl-D-thiogalactopyranoside
- step b) of the process of the invention the IFNa5-producing E. coli host cell is cultured under conditions effective to express said IFNa5 protein by said recombinant IFNa5 producing E. coli host cell in a fermentation medium, with the addition of a carbon feed solution, wherein
- said fermentation medium is free of components of animal origin or from yeast, and
- said carbon feed solution comprises a carbon source and from about 3.0 to about 3.7 mL of a trace element solution per liter of added carbon solution.
- the effective conditions under which the IFNa5-producing E. coli host cell has to be cultured to express said IFNa5 protein in general, is known to those skilled in the art.
- Such conditions include a fermentation medium comprising a nitrogen source, a carbon source and a metal source, suitable for the E. coli host cell to be cultured provided that, according to the present invention, the fermentation medium is free. of components of animal origin or from yeast such as a synthetic chemical fermentation medium.
- ammonia and ammonia dibasic phosphate can be used as a source of nitrogen, alone or in combination.
- the carbon source may be citric acid, glucose or combinations thereof.
- Example 2 describes a fermentation medium for growing a strain of E. coli BL21 (DE3) producing IFNa5, said medium comprising dibasic ammonium phosphate, magnesium sulfate, potassium dihydrogen phosphate, citric acid, D (+) - glucose and a stock of trace elements, wherein said stock of trace elements comprises trace elements selected from the group of trace elements consisting of iron, calcium, zinc, manganese, copper, cobalt, molybdenum, boron and combinations thereof.
- said fermentation medium comprises a source of trace elements selected from the group of sources of trace elements consisting of iron (III) chloride, chloride of calcium, zinc (II) sulfate, manganese (II) sulfate, copper (II) sulfate, cobalt (II) chloride, sodium molybdate, boric acid and combinations thereof.
- a source of trace elements selected from the group of sources of trace elements consisting of iron (III) chloride, chloride of calcium, zinc (II) sulfate, manganese (II) sulfate, copper (II) sulfate, cobalt (II) chloride, sodium molybdate, boric acid and combinations thereof.
- the parent trace element solution comprises (in g / L): iron (III) chloride hexahydrate (30.0), calcium chloride dihydrate (4.05), zinc sulfate (II) heptahydrate ( 6.75), manganese (II) monohydrate sulfate (1.5), copper (II) sulfate pentahydrate (3.0), cobalt (II) chloride hexahydrate (1.14), sodium molybdate dihydrate (0 , 3) and boric acid (0.69) [Example 4].
- the carbon feed solution comprises a carbon source and from about 3.0 to about 3.7 mL of a trace element solution per liter of added carbon feed solution. .
- the characteristics of said trace element solution have been previously defined.
- the carbon feed solution comprises a carbon source (for example, citric acid and / or glucose), magnesium sulfate and, according to the invention, a concentrated solution of trace elements in a concentration from about 3 , 0 mL to approximately 3.7 mL of trace element solution per liter of feed solution is carbon to be added.
- Examples 2 and 4 describe a stock solution of trace elements comprising trace elements selected from the group of trace elements consisting of iron, calcium, zinc, manganese, copper, cobalt, molybdenum, boron and combinations thereof; in a particular embodiment, said trace element stockpile comprises iron (III) chloride, calcium chloride, zinc (II) sulfate, manganese (II) sulfate, copper (II) sulfate, cobalt (II) chloride ), sodium molybdate, boric acid and combinations thereof.
- the stockpile stock solution included in a concentration of about 3.0 mL to about 3.7 mL of trace element solution per liter of solution Carbon feeding is the stockpile solution described in Examples 2 and 4.
- Example 2 describes a hIFNa5 biosynthesis procedure by a producing strain.
- recombinant IFNa5 for example, hIFNa5
- the relative amount of oxidized Met found in a purified active ingredient of a recombinant IFNa5 (for example, a recombinant hIFNa5) produced in E. coli is closely related to the amount of "unprocessed methionine" at the N-terminal end of the polypeptide chain.
- the amount of IFNa5 with oxidized Met (determined by RP-HPLC) after refolding should not constitute more than 1%.
- the inventors observed that the concentration of trace elements in the fermentation medium had an important effect on the post-translational modifications of hIFNa5.
- the form of oxidized methionlated hIFNa5 hIFNa5 with oxidized Met
- the amount of acetylated hIFNa5 forms is reduced twice (in half), when 1 L of the carbon feed solution contains 3.0 mL-3.7 mL of said trace element stock or when it is within the limits of 0.0048 mL / L / u. o. -0.0070 mL / L / u. [u.o .: optical units].
- the process of the invention is performed under conditions in which the "average specific crop growth rate" ( ⁇ ) after induction is equal to or greater than 0.17 [ ⁇ : ((ln D02- ln D01) / T2-T1), where OD is "optical density” (optical units, uo) and T is "time”].
- ⁇ average specific crop growth rate
- the concentration of trace elements in the culture medium is less than 0.95 mL / L of final suspension volume (Example 4, Table 3) or less than 3.0 mL / L of carbon feed solution
- the average ⁇ after the induction reaches only 0.121-0.158, that is, less than 0.17 (M-83, M-84, M-85, M-86).
- the mean ⁇ after induction is less than 0.17
- the presence of the oxidized methionlated hIFNa5 form is practically guaranteed.
- a concentration of trace elements in the culture medium greater than 1.23 mL / L of final volume of suspension results in faster growth (M-89, M-90), higher PCH and greater amount of acetylated IFNa5 form + unknown protein .
- the average ⁇ after induction is equal to or greater than 0.17 the procedure works best until the concentration of trace elements is greater than 1.23 mL / L of final suspension volume or more than 3.7 mL / L of carbon feed solution.
- Step c) of the process of the invention comprises isolating, and, optionally, purifying, the expressed IFNa5 protein.
- the IFNa5 protein is isolated in the form of inclusion bodies (CI) by subjecting said IC to solubilization to obtain a denatured IFNa5 containing mixture that in turn it undergoes an oxidative renaturation treatment to generate a mixture containing renatured IFNa5 which is then subjected to a purification procedure to obtain the corresponding purified IFNa5.
- said IFNa5 is preferably hIFNa5.
- first IFNa5 producing E. coli host cells are lysed to isolate said IFNa5 in the form of inclusion bodies (IC).
- IC inclusion bodies
- the cell membranes of IFNa5-producing E. coli host cells are lysed using conventional techniques such as homogenization, sonication or pressure oscillations (cycles). Preferred methods They include sonication or homogenization with a Poter homogenizer (Teflon / glass).
- ICs containing IFNa5 are separated from the liquid phase of the lysate, for example by centrifugation, and resuspended in an appropriate buffer solution. The ICs can be optionally washed to remove soluble E. coli proteins therein.
- ICs are solubilized in the presence of an agent so lubi 1 i zant e such as a chaotropic agent, for example, a protein denaturant that dissociates the hydrogen bonds and affects the secondary and tertiary structure of the protein producing its deployment , generally in an aqueous buffer solution, to give a mixture comprising denatured IFNa5.
- agent so lubi 1 i zant e such as a chaotropic agent
- a chaotropic agent for example, a protein denaturant that dissociates the hydrogen bonds and affects the secondary and tertiary structure of the protein producing its deployment , generally in an aqueous buffer solution, to give a mixture comprising denatured IFNa5.
- chaotropic agents include urea and guanidinium hydrochloride (GdmHCl), preferably guanidinium hydrochloride, a strong chaotropic agent that prevents carbamoylation of the polypeptide chain (which may
- the concentration of the chaotropic agent will depend on the particular chaotropic agent used and the amount of cellular material present.
- a solution of guanidinium hydrochloride having a concentration of 6-7 M, more preferably 6 M. is used.
- the pH can be adjusted by adding suitable buffers, and, preferably, the pH will be above 7, typically, equal or greater. of about 8, preferably, equal to or greater than 8.6, more preferably, between 9.55 and 9.65, which comprises a chaotropic agent.
- the solubilization of the ICs is performed at the same pH as the refolding step thus avoiding additional pH adjustments of the solubilizer for the refolding step.
- renaturation buffer comprises a stabilizing agent (for example, L-arginine, etc.), a redox pair (for example, GSH / GSSG, etc.) and, optionally, a chelating compound, in a buffer system having a pH above 7.0, typically, equal to or greater than about 8, preferably, equal to or greater than 8.6, more preferably, between 9.55 and 9.65.
- stabilizing agent for example, L-arginine, etc.
- a redox pair for example, GSH / GSSG, etc.
- a chelating compound in a buffer system having a pH above 7.0, typically, equal to or greater than about 8, preferably, equal to or greater than 8.6, more preferably, between 9.55 and 9.65.
- the resulting protein solution containing correctly folded IFNa5 is clarified by conventional techniques, for example, centrifugation or filtration, to remove any remaining particulate matter. Then, if necessary, the pH of the clarified protein solution is adjusted to 8.0-8.20 with a suitable acid (for example mp, HC1) and the mixture comprising rennured IFNa5 (protein solution) is then subjected to Any suitable procedure to purify IFNa5.
- a suitable acid for example mp, HC1
- the invention further provides an effective method for purifying an IFNa5 which comprises subjecting the renatured IFNa5 to a four-step chromatographic method comprising:
- step 2) subject the solution obtained in step 1) to an anion exchange chromatography
- step 3 subject the solution obtained in step 2) to a first cation exchange chromatography
- step 4) subjecting the solution obtained in step 3) to a second cation exchange chromatography, wherein said solution, optionally, is diluted with a buffer comprising methionine.
- the clarified protein solution with the adjusted pH containing a mixture of proteins obtained after the oxidative renaturation treatment is applied, in step 1), to a phenyl-Sepharose column to separate the IFNa5 renatural left of other components, for example, residual chaotropic agents, etc.
- the contact of renatured I FNa 5 with the hydrophobic surface of the adsorbent favors the maturation of IFNa5.
- step 2) the set of proteins obtained in step 1) is adjusted to conductivity (for example, 13.00-14.00 mS / cm) and the pH is adjusted to 8, 75-8, 85 and applied to a Q-Sepharose column (anion exchange chromatography) to separate the IFNa5 monomer from its aggregate forms. Fractions having a specific purity (for example, equal to or greater than 55%) can be combined for further purification.
- step 3 the set of proteins obtained in step 2) is adjusted to conductivity (for example, 6.00-7.00 mS / cm) and the pH is adjusted to 5.15-5.20 and applied to a column of SP-Sepharosa (first cation exchange chromatography) to separate the main IFNa5 form from charged isoforms such as N-methionyl-IFNa5 and acetylated IFNa5 (forms that are products of post-translational modifications). Fractions having a specific purity (for example, equal to or greater than 55%) can be pooled for further purification.
- conductivity for example, 6.00-7.00 mS / cm
- pH is adjusted to 5.15-5.20
- SP-Sepharosa first cation exchange chromatography
- step 4 the set of proteins obtained in step 3) is adjusted to conductivity (for example, 6.00-7.00 mS / cm) and the pH is adjusted to 5.00-5, 20 and applied to a second column of SP-Sepharose (second cation exchange chromatography) to separate the main IFNa5 form from charged isoforms.
- L-methionine is added to the loading solution to prevent oxidation of IFNa5 during chromatography performed at room temperature.
- the fractions can be combined in such a way that an IFNa5 purity equal to or greater than (>) 95% (determined by RP-HPLC) can be achieved.
- the IFNa5 thus obtained can be formulated with pharmaceutically acceptable carriers and excipients, for example, sodium phosphate, pH 6.80-7.20, which contains sodium chloride.
- the protein solution if desired, can be concentrated. to the desired concentration, for example, in a particular embodiment, the protein solution is concentrated to 10 mg / mL, for example, to 1.0-1.5 mg / mL protein concentration, and change the buffer by u 11 rafiltration and sterilize using sterilization by filtration through a sterile filter unit with a maximum pore size of 0.22] i.
- Example 3 describes a procedure to isolate and purify hIFNa5 from a strain producing hIFNa5.
- This example describes the development and construction of the E. coli strain that produces recombinant human interferon alfa-5 (hIFNa5). Briefly, the cloning and expression of the hIFNa5 gene and the construction of the bacterial strain that produces the recombinant IFNa5 protein was achieved as described below by following the steps below: cloning of the cDNA of the gene encoding hIFNa5; modification of the DNA sequence of said gene to optimize its expression in E. coli; construction of the expression plasmid; transformation of the selected plasmid into a suitable strain of E. coli; and selection of expression / induction conditions.
- the coding sequence of hIFNa5 (without signal peptide) from normal liver tissue of an anonymous donor patient - after informed consent - underwent abdominal surgery of a non-hepatic pathology was cloned, as follows: Normal liver tissue was homogenized in 1 mL of Ultraspec solution (Biotex) and the total RNA was treated with DNase (Gibco-BRL, Paisley, RU) before reverse transcription with the M-MLV reverse transcriptase (Gibco-BRL) in the presence of RnasaOUT (Gibco -BRL).
- the hIFNa5 coding sequence (without signal peptide) was amplified by PCR from the complementary DNA (cDNA) previously obtained, using the following direct and reverse primers (5'-3 '):
- Both primers contain hIFNa5 sequence (in bold) and specific sequences for Ndel and BamHI restriction enzymes (underlined).
- the PCR product was analyzed by agarose gel electrophoresis and the band was cut from the gel and purified with the Gene Clean kit (MP Biomedicals).
- the purified PCR product was cloned into plasmid pCR 2.1 TOPO using the TOPO TA cloning kit (Invitrogen).
- the clones of the insert were sequenced on an ABIPRISM 310 genetic analyzer (Perkin Elmer) using the cycle terminator sequencing kit with rhodamine dye (Perkin Elmer) to verify that the insert exactly matched the sequence of hIFNa5.
- pCR 2.1 TOPO-IFNalfa5 was digested with the restriction enzymes Ndel and BamHI, and the 534 bp band (corresponding to the IFNa5 coding sequence) was cloned into the vector pET28b (Novagen) previously digested with the same enzymes . The sequence was verified again using the same procedure.
- Plasmid pET28-IFN alpha-5 was analyzed by sequencing both strands of DNA using an ABI Prism 377 sequence analyzer. This analysis confirmed the hIFNa5 coding sequence. Plasmid pET28-IFN alpha-5 was used for the construction of the mature structure with codon optimization as a template for PCR amplification.
- PCR amplification was performed using plasmid pET28-IFN alpha-5 as a template.
- the following oligonucleotides were synthesized:
- Sense primer 5'- CAT ATG TGT GAT CTG CCG CAG ACC CAC TCC CTG TCT AAC CGT CGT ACT CTG ATG ATC ATG GCA CAG
- Antisense primer 5'- CTG CAG TTA TTC CTT ACG ACG TAA ACG TTC TTG CAA G [SEQ ID NO: 5]
- Primers SP [SEQ ID NO: 4] and ASP [SEQ ID NO: 5] have been applied to replace codons that are less frequently used in E. coli. Codon optimization mainly concerns the arginine codons AGA and AGG.
- Purified amplification products of approximately 500 bp were cloned into plasmid pUC57 / T (# SD0171 Fermentas, Lithuania) using the kit rapid DNA ligation (# K1421, Fermentas, Lithuania) and transformed into E. coli JM109 (ATCC 53323, ATCC Bacteria and Bacteriophages, 19th edition, 1996). Recombinant clones were selected by restriction analysis ( Figure 3). 2 clones were selected and the plasmids extracted were sequenced.
- the hIFNa5 coding fragment was cut with Ndel + BamHI and the purified DNA fragment was ligated into vector pET21b (+) (Novagen) cut with Ndel + BamHI to give plasmid pET21-IFN alpha-5.
- the bacteria were selected by adding 100 g / mL ampicillin.
- the analysis of the recombinant inserts of the colonies resulting from the transformed cells was performed using the colony PCR test method. Detailed restriction analysis of plasmid pET21-IFN alpha-5, purified from PCR positive clones, produced the expected restriction pattern (Figure 5).
- the molecular weight of hIFNa5 is approximately 20 kDa, which correlates with the calculated 19.7 kDa.
- Recombinant hIFNa5 was detected in the insoluble fraction of the total cell lysate; The yield of the target protein was about 20% of the total cell protein.
- the hIFNa5 comprised about 40% of the insoluble fraction of the cell lysate.
- a colony of the expression strain obtained for the establishment of the master research cell bank (RMCB) was used.
- E. coli strain BL21 (DE3) pET21-IFN a-5 (Example 1) was cultured in a medium having the following composition (g / L):
- feed solution A (g / L): D (+) -glucose monohydrate (700.0), magnesium sulfate heptahydrate (20.7) and stock solution of trace elements e) (3.4 mL / L);
- feed solution B (g / L): dibasic ammonium phosphate (360.0) and potassium dihydrogen phosphate (306.7); and e) stock solution of trace elements (g / L): iron (III) chloride hexahydrate (30.0), calcium chloride dihydrate (4.05), zinc sulfate (II) heptahydrate (6.75), sulfate manganese (II) monohydrate (1.5), copper (II) sulfate pentahydrate (3.0), cobalt (II) chloride hexahydrate (1.14), sodium molybdate dihydrate (0.3) and boric acid
- Figure 7 shows the complete scheme of the biosynthesis procedure of human IFN alpha-5.
- Feed solution B [d)] was pumped into separate doses: 150 mL at 60-70 uo, 150 mL at 120-140 uo, 75 mL at 1.5 hours (90 minutes) and 75 mL at 2 hours later of induction. Fermentation continued for 3 hours after induction under the same conditions.
- the cell suspension was then cooled in the thermostat to 12-15 ° C and transferred to a centrifuge by a peristaltic pump (35 L / h). The cell suspension was centrifuged at a speed of 5,000 rpm at 4 ° C.
- 680.0-700.0 g of the biomass obtained in Example 2 were homogenized in a resuspension buffer (0.1 M Tris-HCl, pH 7.80-8.00, containing 2 mM EDTA, Triton X- 100 to 0.1% and 1 mM PMSF) in a 1/10 ratio (weight / volume), that is, 1 g of wet biomass / 10 mL of resuspension buffer.
- a resuspension buffer 0.1 M Tris-HCl, pH 7.80-8.00, containing 2 mM EDTA, Triton X- 100 to 0.1% and 1 mM PMSF
- the resuspension was performed in a homogenized Poter (teflon / glass) and then the cells were broken with a high pressure homogenizer at 600-800 baros at a temperature of 4-10 ° C. After the disintegration of the cells, the inclusion bodies (IC) were separated by centrifugation at 8,000 rpm for 30-35 minutes.
- Wash buffer I 10 mM Tris-HCl buffer, pH 7.45-7.55, with 1 M NaCl, 0.1% polysorbate-80;
- Wash buffer II 10 mM Tris-HCl buffer, pH 8.00-8.20, with 6 M urea;
- Wash buffer III 10 mM Tris-HCl buffer, pH 8.00-8.20. Briefly; IC washing was performed as follows:
- step 1 the first two washes (steps 1 and 2), the ICs were washed with wash buffer I;
- step 3 the third wash (step 3), the ICs were washed with wash buffer II; Y c) the fourth wash (step 4), the ICs were washed with wash buffer III.
- the wash buffer / wet biomass ratio of 10 mL of buffer / 1 g of wet biomass was maintained throughout the IC washing procedure.
- solubilization buffer 50 mM glycine buffer / NaOH, pH 9.55-9.65, with 6 M GdmHCl
- Solubilization ratio Isolated ICs of 1 g of biomass in 6 mL of solubilization buffer for 2 hours at 2-8 ° C, and then centrifugation at 8,000 rpm for 25-30 minutes.
- Renaturation buffer 50 mM glycine / NaOH buffer, pH 8.
- Denatured human IFN alpha 5 with GdmHCl was renatured by dropwise addition of the IC solubilizer to renaturation buffer (volume ratio: 1: 7) to reach a final concentration in the renaturation mixture of L-arginine 0, 2M, GSH / GSSG 2.5 / 0.25mM.
- the renaturation mixture was stirred continuously for 44-66 hours at 2-8 ° C. After renaturation, the protein solution was clarified by centrifugation at 8,000 rpm for 30-35 minutes.
- the hIFNa5 was purified by a four-step critical process as mentioned below.
- the phenyl-Sepharose column is indicated to separate renatured hIFNa5 from the residual chaotropic agent GdmHCl.
- the contact of hIFNa5 renaturalized with the hydrophobic surface of the adsorbent favors the maturation of hIFNa5.
- the pH of the clarified protein solution was adjusted to 8.00-8.20 with 6M HC1 and the protein solution was then applied to a phenyl-Sepharose chromatography column with the following procedure parameters:
- Elution buffer 10 mM Tris-HCl buffer, pH 9.20-9.25, conductivity 0.1-0.2 mS / cm at 15-25 ° C;
- Elution is performed with 6 column volumes (VC) [ie 6VC] with elution buffer. Protein solution collected 2-6 VC.
- the Q-Sepharose column is used to separate the hIFNa5 monomer from its aggregate forms.
- the set of proteins obtained in the previous step (5.1) was adjusted to a conductivity of 13.00-14.00 mS / cm by adding 20 mM Tris-HCl buffer, pH 8.75-8.85, with NaCl 5 M, and the pH was adjusted to 8, 75-8, 85 with 6 M HC1.
- the protein solution was then applied to a Q-Sepharosa chromatography column with the following procedure parameters:
- Balancing buffer 20 mM Tris-HCl buffer, pH 8.75-8.85, with 0.12 M sodium chloride, conductivity 13.00-14.00 mS / cm at 15-25 ° C;
- Elution buffer 20 mM Tris-HCl buffer, pH 8.75-8.85, with 0.23 mM sodium chloride, conductivity 23.00-25.00 mS / cm a
- Elution linear gradient up to 100% elution buffer in 5 column volumes (5VC) and 5VC 100% elution buffer.
- the volume of fractions was 400-1,000 mL.
- the SP-Sepharose column is used for the third and fourth chromatography steps to separate the main hIFNa5 form from charged isoforms such as N-methionyl-hl FNa5 and acetylated hIFNa5 (forms that are products of post-translational modifications).
- the protein set obtained in the previous step (5.2) was adjusted to a conductivity of 6.00-7.00 mS / cm by adding 10 mM sodium acetate buffer, pH 4.95-5.050 and the pH adjusted to 5.15-5.20 with 4M acetic acid.
- the protein solution was then applied to a SP-Sepharosa chromatography column with the following procedure parameters:
- Elution was performed in 10 column volumes (10VC) with elution buffer.
- the volume of fractions was 400-2,000 mL.
- the loading solution [mixture of the SP-Sepharosa first column protein fraction (step 5.3)] was diluted with 5 mM sodium acetate buffer, pH 5.00-5.20, with 2 mM methionine, conductivity from 0.200-0.800 mS / cm at 15-25 ° C, up to a conductivity of 6.00-7.00 mS / cm.
- the inclusion of 2 mM L-methionine in the loading solution was made to prevent oxidation of hIFNa5 during chromatography performed at room temperature.
- the loading solution was applied to a SP-Sepharosa chromatography column with the following procedure parameters:
- Bed volume of chromatography medium 3.0 ⁇ 0.3 L
- Balancing buffer 20 mM sodium acetate buffer, pH 5.15-5.20, with 50 mM sodium chloride, conductivity 6.00-7, 00 mS / cm at 15-25 ° C;
- Elution buffer 20 mM sodium acetate buffer, pH 5.15-5.20, with 0.1 M sodium chloride, conductivity 11.00-13.00 mS / cm at 15-25 ° C;
- Elution linear gradient to 100% elution buffer in 20 column volumes (20VC). The volume of fractions was 400-2,000 mL.
- Formulation buffer 25 mM sodium phosphate, pH 6.80-7.20, with 0.1 M sodium chloride, conductivity 10.00-14.00 mS / cm at 15-25 ° C.
- the buffer / concentration exchange of the protein solution was carried out by diafiltration / concentration through a 10 kDa Biomax membrane equal to or greater than ( ⁇ ) 1.00 mg / ml, sterilized by filtration through a sterile filter 0.22 ⁇ (Millipak 20) and glass vials were filled.
- Figure 8 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by SDS-PAGE (14%) both under reducing and non-reducing conditions of the recombinant hIFNa5 protein from three large-scale purification lots.
- Figure 9 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by "reverse phase high performance liquid chromatography" (RP-HPLC) analysis (the figure shows the results of three large-scale batches of recombinant hIFNa5) .
- RP-HPLC reverse phase high performance liquid chromatography
- Figure 10 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by "high performance liquid chromatography” (SE-HPLC) analysis for three large-scale batches of recombinant hIFNa5.
- SE-HPLC high performance liquid chromatography
- Figure 11 shows the purity of the recombinant hIFNa5 processed and formulated according to this invention determined by isoelectric focusing analysis for three large-scale batches of recombinant hIFNa5.
- Lanes 1, 11 pl standards (Amersham Pharmacia); lanes 2, 3, 4: recombinant hIFNa5, 15 g; lanes 5, 6, 7: recombinant hIFNa5, 5] ig; lanes 8, 9, 10: recombinant hIFNa5, 1 g.
- Figure 12 depicts the large-scale three-batch peptide mapping chromatograms of purified and formulated recombinant hIFNa5 preparations according to the invention.
- EXAMPLE 4 EXAMPLE 4
- this example was to confirm the effect of trace elements on posttranslational modifications of recombinant human IFN alpha-5 (hIFNa5), to determine the critical concentration limits of trace elements in the carbon feed solution and to evaluate the effect of glucose concentration in the biosynthesis of recombinant hIFNa5.
- this example describes the analysis performed and the results obtained during the study and serves as a justification of the concentration of trace elements in the carbon feed solution and justification of the glucose concentration in the recombinant hIFNa5 biosynthesis procedure.
- Fermentations were carried out in batches fed with high cell density in a chemically defined medium of mineral salts / glucose.
- composition of the mineral salts / glucose medium for bottle culture (g / L): disodium hydrogen phosphate - 17.0, potassium dihydrogen phosphate - 1.82, ammonium sulfate - 3.0, magnesium sulfate heptahydrate - 0.5 , D (+) -glucose monohydrate - 15.0, stock solution of trace elements - 0.16 mL.
- composition of the mineral salts / glucose medium for fermentation (g / L): dibasic ammonium phosphate - 4.0, magnesium sulfate heptahydrate - 0.5, potassium dihydrogen phosphate - 13.3, citric acid monohydrate - 1.6, D (+) - glucose monohydrate - 30.0, stock solution of trace elements - 0.25 mL.
- Carbon feed solution 70.0% glucose, MgS0 4 x7H 2 0 2.1% and stockpile solution according to the experimental plan.
- Glucose concentration was measured from the culture every 8 or (15-30) minutes after that a calculated dose was added (to reach the upper limit of the glucose concentration of 17 g / L or 22 g / L as the experimental plan) of carbon feeding.
- both phosphate solutions dibasic ammonium phosphate - 25.0 g, potassium dihydrogen phosphate - 21.0 g divided into 3 doses: 2: 2: 1 ratio or 28:28:14 mL
- 70 mL of both phosphate solutions were added in separate doses at 60-75, 120-135 and 170-180 uo
- the inlet air was automatically enriched with pure oxygen (up to 60% per liter of total fermenter volume) to maintain the dissolved oxygen concentration at 20%.
- the inoculum was about 1.0% (20 mL) of the fermenter's work volume, which is 1.54% of the actual volume.
- the fermentations were carried out in a "Biostat B” fermenter with a total volume of 3 L / working 2 L at pH 6.8, 20% p0 2 , temperature 37 ° C.
- the fermentation process variables automatically controlled in line (temperature, stirring, pH, p0 2 , acid / base consumption) and the off-line variable - optical density were plotted in MFCS / in graphs.
- the oxidized methionlated hIFNa5 related protein was removed when the concentration of trace elements (stock solution) was equal to or greater than 3.0 mL / L of carbon feed solution or equal to or greater than 0.95 mL / L of actual final volume of the suspension and the average specific growth rate of growth ( ⁇ ) after induction was equal to or greater than (>) 0.17 (Tables 2-3).
- Table 2 shows the biosynthesis parameters at different concentrations of trace elements in the carbon feed solution while Table 3 shows the parameters of biosynthesis and refolding at different concentrations of trace elements.
- the amount of acetylated hIFNa5 is around 8-11% when the concentration of trace elements (stock solution) is within the limits of 3.0-3.7 mL / L of carbon feed solution (small batches No. M-80 , M-81, M- 92, M-82 and M-87) or within the limits of 0.95-1.23 mL / L of actual final volume of suspension (Table 3); Y
- the oxidized methionlated hIFNa5 protein is removed when the concentration of trace elements is equal to or greater than 3.0 mL / L of carbon feed solution or greater than 0.95 mL / L actual final volume of suspension and the growth rate of the crop Specific ( ⁇ ) mean after induction is equal to or greater than 0.17.
- Acetylated hIFNa5 protein is around 8-11% when the concentration of trace elements is in the range of about 3.0 to about 3.7 mL / L of carbon feed solution or about 0.95 to about 1.23 mL / L actual final volume of suspension.
- the optimal concentration of trace elements that determines the maximum yield and the best quality of the target hIFNa5 protein is within the limits of approximately
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2788607A CA2788607C (en) | 2010-02-01 | 2011-01-31 | Process for the production of interferon alpha 5 |
EP11712277.0A EP2532734B1 (en) | 2010-02-01 | 2011-01-31 | Process for the production of interferon alpha 5 |
CN201180013665.0A CN102869767B (zh) | 2010-02-01 | 2011-01-31 | 干扰素α5的制备方法 |
BR112012018956-5A BR112012018956B1 (pt) | 2010-02-01 | 2011-01-31 | Processo para produção de uma proteína interferon alfa 5 |
KR1020127023051A KR101858598B1 (ko) | 2010-02-01 | 2011-01-31 | 인터페론 알파 5의 제조방법 |
MX2012008893A MX2012008893A (es) | 2010-02-01 | 2011-01-31 | Procedimiento para la produccion de interferon alfa 5. |
AU2011209506A AU2011209506A1 (en) | 2010-02-01 | 2011-01-31 | Method for producing interferon alpha 5 |
NZ601616A NZ601616A (en) | 2010-02-01 | 2011-01-31 | Method for producing interferon alpha 5 |
RU2012137428A RU2575598C9 (ru) | 2010-02-01 | 2011-01-31 | Способ получения белка альфа5-интерферона |
US13/576,068 US8709757B2 (en) | 2010-02-01 | 2011-01-31 | Method for producing interferon alpha 5 |
JP2012550482A JP5830032B2 (ja) | 2010-02-01 | 2011-01-31 | インターフェロンアルファ5を生産する方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382019 | 2010-02-01 | ||
EP10382019.7 | 2010-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011092367A1 true WO2011092367A1 (es) | 2011-08-04 |
Family
ID=43920729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2011/070057 WO2011092367A1 (es) | 2010-02-01 | 2011-01-31 | Procedimiento para la producción de interferón alfa 5 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8709757B2 (es) |
EP (1) | EP2532734B1 (es) |
JP (1) | JP5830032B2 (es) |
KR (1) | KR101858598B1 (es) |
CN (1) | CN102869767B (es) |
AU (1) | AU2011209506A1 (es) |
BR (1) | BR112012018956B1 (es) |
CA (1) | CA2788607C (es) |
MX (1) | MX2012008893A (es) |
NZ (1) | NZ601616A (es) |
RU (1) | RU2575598C9 (es) |
WO (1) | WO2011092367A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864915B (zh) * | 2012-12-07 | 2016-06-08 | 天津未名生物医药有限公司 | 纯化重组人干扰素α2b的方法和试剂盒 |
CN104356223B (zh) * | 2014-11-26 | 2017-11-10 | 安徽安科生物工程(集团)股份有限公司 | 高纯度重组人干扰素α2b的制备方法 |
LT6861B (lt) | 2021-04-02 | 2021-11-10 | Kauno technologijos universitetas | Maitinimo profilių, skirtų valdyti pusiau-periodinius rekombinantinių E. coli kultivavimo procesus, formavimo ir adaptavimo būdas |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983002459A1 (en) | 1982-01-15 | 1983-07-21 | Cetus Corp | Interferon-alpha 61 |
US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4569908A (en) * | 1982-01-19 | 1986-02-11 | Cetus Corporation | Multiclass hybrid interferons |
US4765903A (en) | 1987-10-06 | 1988-08-23 | Interferon Sciences, Inc. | Purification of monomeric interferon |
US4845032A (en) | 1985-03-27 | 1989-07-04 | Hoechst Aktiengesellschaft | Process for the isolation and purification of alpha-interferons |
WO1997021829A1 (de) * | 1995-12-11 | 1997-06-19 | Merck Patent Gmbh | Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation |
EP1310559A1 (en) | 2001-11-08 | 2003-05-14 | International Centre for Genetic Engineering and Biotechnology | Process for the production of alpha interferon of therapeutical degree |
WO2005087940A1 (en) * | 2004-03-11 | 2005-09-22 | Wisconsin Alumni Research Foundation | Genetically altered microorganisms with modified metabolism |
EP1990349A1 (en) | 2007-05-09 | 2008-11-12 | Institut Pasteur | Method for the production of high-level soluble human recombinant interferon alpha in E. coli and vectors useful for such a production |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
US5814485A (en) * | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
ES2138565B1 (es) | 1998-05-13 | 2000-08-16 | Inst Cientifico Tecnol Navarra | Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. |
NZ540895A (en) * | 2003-01-09 | 2007-03-30 | Genentech Inc | Purification of polypeptides with ethacridine lactate |
CA2609205A1 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
-
2011
- 2011-01-31 EP EP11712277.0A patent/EP2532734B1/en not_active Not-in-force
- 2011-01-31 BR BR112012018956-5A patent/BR112012018956B1/pt active IP Right Grant
- 2011-01-31 CA CA2788607A patent/CA2788607C/en active Active
- 2011-01-31 AU AU2011209506A patent/AU2011209506A1/en not_active Abandoned
- 2011-01-31 RU RU2012137428A patent/RU2575598C9/ru active
- 2011-01-31 NZ NZ601616A patent/NZ601616A/xx unknown
- 2011-01-31 MX MX2012008893A patent/MX2012008893A/es active IP Right Grant
- 2011-01-31 US US13/576,068 patent/US8709757B2/en active Active
- 2011-01-31 CN CN201180013665.0A patent/CN102869767B/zh active Active
- 2011-01-31 JP JP2012550482A patent/JP5830032B2/ja active Active
- 2011-01-31 WO PCT/ES2011/070057 patent/WO2011092367A1/es active Application Filing
- 2011-01-31 KR KR1020127023051A patent/KR101858598B1/ko active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983002459A1 (en) | 1982-01-15 | 1983-07-21 | Cetus Corp | Interferon-alpha 61 |
US4569908A (en) * | 1982-01-19 | 1986-02-11 | Cetus Corporation | Multiclass hybrid interferons |
US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4845032A (en) | 1985-03-27 | 1989-07-04 | Hoechst Aktiengesellschaft | Process for the isolation and purification of alpha-interferons |
US4765903A (en) | 1987-10-06 | 1988-08-23 | Interferon Sciences, Inc. | Purification of monomeric interferon |
WO1997021829A1 (de) * | 1995-12-11 | 1997-06-19 | Merck Patent Gmbh | Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation |
EP1310559A1 (en) | 2001-11-08 | 2003-05-14 | International Centre for Genetic Engineering and Biotechnology | Process for the production of alpha interferon of therapeutical degree |
WO2005087940A1 (en) * | 2004-03-11 | 2005-09-22 | Wisconsin Alumni Research Foundation | Genetically altered microorganisms with modified metabolism |
EP1990349A1 (en) | 2007-05-09 | 2008-11-12 | Institut Pasteur | Method for the production of high-level soluble human recombinant interferon alpha in E. coli and vectors useful for such a production |
Non-Patent Citations (22)
Title |
---|
"ATCC 53323, ATCC Bacteria and Bacteriophages", 1996 |
"Current Protocols in Molecular Biology", vol. 1-3, 1994, JOHN WILEY & SONS |
"Current Protocols in Molecular Biology", vol. 1-3, 1994, JOHN WILEY & SONS, INC. |
"Sambrook", 1989, CSH LABORATORY, COLD SPRING HARBOR, article "Molecular cloning: A Laboratory Manual. Second" |
BARON, NARULA, CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 10, no. 3, 1990, pages 179 - 190 |
BEDARRAIN ET AL., BIOTECHNOL. APPL. BIOCHEM., vol. 33, 2001, pages 173 - 182 |
DERYNCK ET AL., NATURE, vol. 287, 1980, pages 193 - 197 |
E. COLI ET AL.: "soon after it was first cloned", GOEDELL ET AL. NATURE., vol. 287, 1980, pages 411 - 416 |
KENSY FRANK ET AL: "Scale-up from microtiter plate to laboratory fermenter: evaluation by online monitoring techniques of growth and protein expression in Escherichia coli and Hansenula polymorpha fermentations", MICROBIAL CELL FACTORIES, BIOMED CENTRAL, LONDON, NL, vol. 8, no. 1, 22 December 2009 (2009-12-22), pages 68, XP021067676, ISSN: 1475-2859 * |
KHALILZADEH R ET AL: "Process development for production of recombinant human interferon-gamma expressed in Escherichia coli", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, vol. 31, no. 2, February 2004 (2004-02-01), pages 63 - 69, XP002637566, ISSN: 1367-5435 * |
KORZ D J ET AL: "Simple fed-batch technique for high cell density cultivation of Escherichia coli", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 39, no. 1, 21 February 1995 (1995-02-21), pages 59 - 65, XP004037076, ISSN: 0168-1656, DOI: DOI:10.1016/0168-1656(94)00143-Z * |
MIZOGUCHI ET AL., DNA, vol. 4, 1985, pages 221 - 32 |
NAGATA ET AL., NATURE, vol. 284, 1980, pages 316 - 320 |
PACK P ET AL: "IMPROVED BIVALENT MINIANTIBODIES, WITH IDENTICAL AVIDITY AS WHOLE ANTIBODIES, PRODUCED BY HIGH CELL DENSITY FERMENTATION OF ESCHERICHIA COLI", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 11, no. 11, 1 November 1993 (1993-11-01), pages 1271 - 1277, XP000608190, ISSN: 0733-222X * |
PESTKA ET AL., ANN. REV. BIOCHEM., vol. 56, 1987, pages 727 - 777 |
PESTKA, S. ARCH. BIOCHEM. BIOPHYS., vol. 221, no. 1, 1983, pages 1 - 37 |
SAMBROOK ET AL.: "Molecular cloning: A Laboratory Manual", 1989, CSH LABORATORY, COLD SPRING HARBOR |
SRIVASTA ET AL., PROT. EXPRESS. PURIF, vol. 41, 2005, pages 313 - 322 |
SWAMINATHAN ET AL., PROT EXPRESS. PURIF, vol. 15, 1999, pages 236 - 242 |
TATUTSOVA, MADDEN, FEMS MICROBIOL. LETT., vol. 174, 1990, pages 247 - 250 |
THATCHER, PANAYOTATOS, METHODS ENZYMOL., vol. 119, 1986, pages 166 - 177 |
VILLAVERDE, CARRIO, BIOTECHNOL. LETT., vol. 25, 2003, pages 1385 - 1395 |
Also Published As
Publication number | Publication date |
---|---|
BR112012018956B1 (pt) | 2022-05-31 |
US8709757B2 (en) | 2014-04-29 |
JP2013517788A (ja) | 2013-05-20 |
CA2788607C (en) | 2018-03-20 |
CA2788607A1 (en) | 2011-08-04 |
MX2012008893A (es) | 2013-02-27 |
CN102869767A (zh) | 2013-01-09 |
US20120309057A1 (en) | 2012-12-06 |
EP2532734B1 (en) | 2017-03-15 |
RU2575598C9 (ru) | 2016-04-27 |
RU2012137428A (ru) | 2014-03-10 |
KR101858598B1 (ko) | 2018-05-16 |
BR112012018956A2 (pt) | 2015-09-15 |
CN102869767B (zh) | 2016-03-09 |
RU2575598C2 (ru) | 2016-02-20 |
NZ601616A (en) | 2013-04-26 |
KR20120125641A (ko) | 2012-11-16 |
AU2011209506A1 (en) | 2012-08-23 |
EP2532734A1 (en) | 2012-12-12 |
JP5830032B2 (ja) | 2015-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4637913B2 (ja) | ヒトインターフェロンベータ変異体 | |
EP0155549B1 (en) | Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide | |
JP4317890B2 (ja) | 疎水性ポリペプチドの細菌生産 | |
AU2005283025A1 (en) | Muteins of fibroblast growth factor 21 | |
US20070293660A1 (en) | Method for purifying granulocyte-colony stimulating factor | |
WO2011092367A1 (es) | Procedimiento para la producción de interferón alfa 5 | |
AU3055789A (en) | Cleaved dimers of mullerian inhibiting substance-like polypeptides | |
JP2008507297A (ja) | 最適化されたインターフェロンβ遺伝子 | |
US20060173167A1 (en) | Process for the purification of recombinant polypeptides | |
EP3057982B1 (en) | Fused proteins of interferon alpha 5 with another cytokine and a process for producing thereof | |
ES2281822T3 (es) | Vectores de expresion, celulas huesped transformadas y procedimiento de fermentacion para la produccion de polipeptidos recombinantes. | |
JP2023522423A (ja) | インターフェロンアルファ2バリアント及びその使用 | |
JPH11508134A (ja) | 肥満症蛋白質中間体およびその製法と使用 | |
JPS615096A (ja) | 新規ポリペプチドおよびその製造法 | |
EP2912173B1 (en) | Process for preparation and purification of recombinant human oncostatin m protein | |
WO2011147138A1 (zh) | 靶向性白细胞介素融合蛋白及其制备方法与应用 | |
Yan et al. | Expression, refolding, and characterization of GFE peptide-fused human interferon-α2a in Escherichia coli | |
Ersoy | Granulocyte-colony stimulating factor analog production by recombinant Escherichia coli | |
WO2011103325A1 (en) | Methods for preparing human growth hormone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180013665.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11712277 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2788607 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012550482 Country of ref document: JP Ref document number: 13576068 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/008893 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011209506 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2011209506 Country of ref document: AU Date of ref document: 20110131 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7412/CHENP/2012 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2011712277 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011712277 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127023051 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012137428 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012018956 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012018956 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120730 |